معرفی
Abbas Ali Qayyum is a Clinical Associate Professor in the Department of Clinical Medicine at the University of Copenhagen, specializing in Cardiology within the Faculty of Health and Medical Sciences. His research primarily focuses on innovative stem cell therapies for heart conditions, particularly mesenchymal stromal cell treatments for various forms of heart failure.
Dr. Qayyum's research interests span multiple areas of cardiology and regenerative medicine:
- Stem cell therapy for heart failure (both ischemic and non-ischemic)
- Mesenchymal stromal cell applications in cardiac regeneration
- Cardiac imaging techniques including CT and MRI
- Peripartum cardiomyopathy and maternal heart conditions
- Clinical trial design for cardiovascular interventions
His publication record demonstrates significant contributions to the field of cardiology, with several high-impact papers that have been referenced in clinical guidelines and picked up by major news outlets. His work on the SCIENCE trials has particularly advanced the understanding of stem cell therapies for heart failure, showing promising results for both ischemic and non-ischemic heart failure patients. His research also extends to hepatocellular carcinoma treatment, demonstrating his interdisciplinary approach to medical research.
Dr. Qayyum has received recognition through:
- Publications referenced in 3 clinical guideline sources
- Research picked up by 9 news outlets
- Substantial citation counts across multiple publications (including over 200 citations for his work on hepatocellular carcinoma)
- Significant social media engagement with his research (37 X users sharing one publication)
Dr. Qayyum maintains active collaborations with researchers across multiple Danish institutions, working closely with colleagues like J. Kastrup, M. Haack-Sørensen, and A.B. Mathiasen on numerous clinical trials. His work bridges the gap between basic science and clinical application, particularly in the area of regenerative medicine for heart conditions, with several ongoing trials showing promising results for patients with limited treatment options.
